ImStem was incorporated in 2012.

As an innovative biopharmaceutical company,
we aspire to improve patients' treatment outcomes and quality of life,

targeting areas in autoimmune,
degenerative, and rare diseases.

T-MSC

T-MSC technology is based on ImStem’s patented
differentiation technology, which can differentiate
human embryonic stem cells (hESCs) into
mesenchymal stem cells (MSCs) with high efficiency,
consistency, and quality, through a trophoblast-like
intermediate stage.

The MSC derived with this proprietary technology is
called T-MSC.

Currently the clinical trial to study the proprietary T-MSC (IMS001)cell therapy in patients with multiple sclerosis is under way. IMS001 is a human embryonic cell (hESC) derived mesenchymal stem cell (MSC) investigational drug.

The Phase I study is enrolling patients who meet the following criteria.